May 21, 2013 - Characterization of Survival Outcome and Application of the International. mRCC Database .... inant histological subtype in the development and valida- ..... son has been a consultant and played an advisory role at Pfizer and.
Original Article
Metastatic Non-Clear Cell Renal Cell Carcinoma Treated With Targeted Therapy Agents Characterization of Survival Outcome and Application of the International mRCC Database Consortium Criteria Nils Kroeger, MD1,2; Wanling Xie, PhD3; Jae-Lyn Lee, MD4; Georg A. Bjarnason, MD5; Jennifer J. Knox, MD6; Mary J. MacKenzie, MD7; Lori Wood, MD8; Sandy Srinivas, MD9; Ulka N. Vaishamayan, MD10; Sun-Young Rha, MD11; Sumanta K. Pal, MD12; Takeshi Yuasa, MD13; Frede Donskov, MD14; Neeraj Agarwal, MD15; Christian K. Kollmannsberger, MD16; Min-Han Tan, MD17; Scott A. North, MD18; Brian I. Rini, MD19; Toni K. Choueiri, MD3,20,21; and Daniel Y.C. Heng, MD1
BACKGROUND: This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized. METHODS: Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGFand mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria RESULTS: The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P
![Sunitinib rechallenge in metastatic renal cell ... - Wiley Online Library [PDF]](https://m.moam.info/img/260x300/sunitinib-rechallenge-in-metastatic-renal-cell-wil_64a08974098a9e57598b45f2.jpg)
